Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deflazacort - Marathon Pharmaceuticals

Drug Profile

Deflazacort - Marathon Pharmaceuticals

Alternative Names: 21 desacetyl DFZ prodrug; DFZ; EMFLAZA; MP-104

Latest Information Update: 18 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marathon Pharmaceuticals
  • Developer Marathon Pharmaceuticals; PTC Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Glucocorticoids; Oxazoles; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy
  • Discontinued Limb girdle muscular dystrophies

Most Recent Events

  • 22 Apr 2023 Pharmacokinetics, efficacy and safety data from a preclinical study in Duchenne muscular dystrophy presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
  • 27 Jun 2022 PTC Therapeutics terminates phase III trial due to low enrollment and missing efficacy assessment data related to COVID-19.in Muscular dystrophy in US, Canada, Denmark, France, Germany, Norway, Russia and Sweden (NCT03783923)
  • 24 Jun 2021 Pooled efficacy data from clinical trials in Duchenne muscular dystrophy released by PTC Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top